PMC10117981_01
CT imaging changes in the course of furomertinib treatment.
(A, B) CT imaging changes of liver. (C) CT imaging changes of pancreas. Arrow: Hepatic metastasis; Dotted line: Hepatic abscess.
fonc-13-1151178-g001.jpg
PMC10117981_01_fonc-13-1151178-g001.jpg
f1
The progression-free survival (PFS) of furmonertinib was 4.7 months ( Figures 1 ,  2 ).
CA19-9 changes throughout the process.
fonc-13-1151178-g002.jpg
PMC10117981_01_fonc-13-1151178-g002.jpg
f2
The progression-free survival (PFS) of furmonertinib was 4.7 months ( Figures 1 ,  2 ).
Flow chart of treatment.
fonc-13-1151178-g003.jpg
PMC10117981_01_fonc-13-1151178-g003.jpg
f3
CT showed that liver metastases increased and enlarged compared with the previous period, with the largest being about 5.7cm x 3.6cm, suggesting that the effect of nimotuzumab combined with chemotherapy was not good ( Figure 3 ).